Hansa Biopharma AB (publ) (HNSBF) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

hnsbf · pe ratio · data through Jun 9, 2026

Core PE Ratio Metrics

Trailing 12 months · TTM

Insufficient PE history data (fewer than 3 valid fiscal years).

PE Ratio vs Peers

Biotechnology · 4 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
Hansa Biopharma AB (publ)You HNSBF	$246M	N/A	—	—
Cellectis S.A. CMVLF	$251M	N/A	—	-$0.70
Frontage Holdings Corporation FGHQF	$304M	44.63x	—	$0.00
Mayne Pharma Group Limited MAYNF	$126M	N/A	—	-$1.14
hVIVO plc OPORF	$241M	N/A	—	-$0.01

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Hansa Biopharma AB (publ) (HNSBF) measures how much investors pay for each dollar of the company's trailing earnings. HNSBF's current PE ratio of N/A is calculated by dividing its stock price of $2.90 by its TTM earnings per share of —.

PE Ratio = Stock Price ÷ EPS (TTM)

= $2.90 ÷ — = N/A

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

HNSBF pe ratio · 6 questions

HNSBF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.90 and TTM EPS of —. Data sourced from Financial Modeling Prep via HNSBF's SEC 10-K and 10-Q filings.

HNSBF PE ratioWhat is HNSBF PE ratioCurrent PE ratio of HNSBFHNSBF PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Hansa Biopharma AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09